Hong Wu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1218918/publications.pdf

Version: 2024-02-01

46	8,474	136940	243610
papers	citations	32 h-index	44 g-index

50	50	50	11095
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Computational characterization of domainâ€segregated 3D chromatin structure and segmented DNA methylation status in carcinogenesis. Molecular Oncology, 2022, 16, 699-716.	4.6	7
2	Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3KÎ±/Î²/Î´ treatment. Nature Communications, 2022, 13, 182.	12.8	40
3	Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia. Blood Science, 2022, 4, 16-28.	0.9	8
4	3D genome alterations associated with dysregulated HOXA13 expression in high-risk T-lineage acute lymphoblastic leukemia. Nature Communications, 2021, 12, 3708.	12.8	24
5	PTEN in Regulating Hematopoiesis and Leukemogenesis. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036244.	6.2	12
6	TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism. Nature Communications, 2020, 11, 1880.	12.8	65
7	Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3KÎ±/Î²/Î´ Inhibitor BAY1082439. Molecular Cancer Therapeutics, 2018, 17, 2091-2099.	4.1	7
8	T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1. ELife, 2018, 7, .	6.0	32
9	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Molecular Systems Biology, 2017, 13, 914.	7.2	73
10	Mammalian non-CG methylations are conserved and cell-type specific and may have been involved in the evolution of transposon elements. Scientific Reports, 2016, 6, 32207.	3.3	8
11	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nature Medicine, 2016, 22, 379-387.	30.7	94
12	Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2016, 15, 1043-1052.	4.1	85
13	Methods for PTEN in Stem Cells and Cancer Stem Cells. Methods in Molecular Biology, 2016, 1388, 233-285.	0.9	11
14	Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma. Oncotarget, 2016, 7, 72860-72867.	1.8	15
15	The Landscape of Somatic Chromosomal Copy Number Aberrations in GEM Models of Prostate Carcinoma. Molecular Cancer Research, 2015, 13, 339-347.	3.4	10
16	Nitroxoline induces apoptosis and slows glioma growth in vivo. Neuro-Oncology, 2015, 17, 53-62.	1.2	41
17	Tracking and Functional Characterization of Epithelialâ€“Mesenchymal Transition and Mesenchymal Tumor Cells during Prostate Cancer Metastasis. Cancer Research, 2015, 75, 2749-2759.	0.9	186
18	PTEN regulates cilia through Dishevelled. Nature Communications, 2015, 6, 8388.	12.8	55

#	Article	IF	Citations
19	A Unified Nomenclature and Amino Acid Numbering for Human PTEN. Science Signaling, 2014, 7, pe15.	3.6	50
20	Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression. Molecular and Cellular Biology, 2014, 34, 2017-2028.	2.3	107
21	Ubiquitin E3 ligase Nedd4-1 acts as a downstream target of PI3K/PTEN-mTORC1 signaling to promote neurite growth. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13205-13210.	7.1	110
22	Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia. Cancer Research, 2014, 74, 7048-7059.	0.9	46
23	Pten loss in the bone marrow leads to G-CSFâ€“mediated HSC mobilization. Journal of Experimental Medicine, 2013, 210, 2337-2349.	8.5	36
24	Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells. Cancer Research, 2012, 72, 1878-1889.	0.9	421
25	Determining PTEN Functional Status by Network Component Deduced Transcription Factor Activities. PLoS ONE, 2012, 7, e31053.	2.5	10
26	Identification of CD166 as a Surface Marker for Enriching Prostate Stem/Progenitor and Cancer Initiating Cells. PLoS ONE, 2012, 7, e42564.	2.5	91
27	Targeting Metabolism in Liposarcomas. FASEB Journal, 2012, 26, 551.6.	0.5	0
28	Suppression of leukemia development caused by PTEN loss. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1409-1414.	7.1	64
29	Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth. Cancer Cell, 2011, 19, 792-804.	16.8	449
30	Loss of Pten Causes Tumor Initiation Following Differentiation of Murine Pluripotent Stem Cells Due to Failed Repression of Nanog. PLoS ONE, 2011, 6, e16478.	2.5	16
31	PtenDeletion in Adult Neural Stem/Progenitor Cells Enhances Constitutive Neurogenesis. Journal of Neuroscience, 2009, 29, 1874-1886.	3.6	245
32	Linâ^'Sca-1+CD49fhigh Stem/Progenitors Are Tumor-Initiating Cells in the Pten-Null Prostate Cancer Model. Cancer Research, 2009, 69, 8555-8562.	0.9	175
33	Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature, 2008, 453, 529-533.	27.8	223
34	Hydrophobic surfaces for enhanced differentiation of embryonic stem cell-derived embryoid bodies. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14459-14464.	7.1	133
35	Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development. Cancer Research, 2007, 67, 6083-6091.	0.9	158
36	Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1480-1485.	7.1	302

#	Article	IF	Citations
37	Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature, 2006, 441, 475-482.	27.8	1,217
38	PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature, 2006, 441, 518-522.	27.8	767
39	PTEN negatively regulates neural stem cell self-renewal by modulating G₀-G₁cell cycle entry. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 111-116.	7.1	281
40	CAPTURING SIGNAL ANOMALIES OF HUMAN PROSTATE CANCER INTO MOUSE MODELS. , 2005, , 393-421.		1
41	PTEN deletion in Bergmann glia leads to premature differentiation and affects laminar organization. Development (Cambridge), 2005, 132, 3281-3291.	2.5	93
42	PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell, 2003, 3, 117-130.	16.8	472
43	Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 2003, 4, 209-221.	16.8	982
44	Essential Role of AKT-1/Protein Kinase BÎ± in PTEN-Controlled Tumorigenesis. Molecular and Cellular Biology, 2002, 22, 3842-3851.	2.3	136
45	Cre/loxP-mediated inactivation of the murinePten tumor suppressor gene. Genesis, 2002, 32, 148-149.	1.6	352
46	Negative Regulation of Neural Stem/Progenitor Cell Proliferation by the Pten Tumor Suppressor Gene in Vivo. Science, 2001, 294, 2186-2189.	12.6	761